Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 13,145

Document Document Title
WO/2018/067423A1
Compounds of general formula (la), compounds of general formula (la'), compounds of general formula (lb), compounds of general formula (lb'), compounds of general formula (I), compounds of general formula (Ι'), and their pharmaceuticall...  
WO/2018/064632A1
Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treat...  
WO/2018/059537A1
The present invention relates to a diazaspiro[5.5]undecane derivative and a use thereof. The derivative is a compound represented by general formula (I) or a stereoisomer, hydrate, metabolite, solvate, pharmaceutically acceptable salt, e...  
WO/2018/060742A1
The present invention relates to a class of substituted-cyanopyrrolidines of Formula (I) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30)...  
WO/2018/055402A1
The present invention relates to compounds of formula (I), and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity: (Formula (I)) wherein X, R1, R2, and n are each as defined her...  
WO/2018/057884A1
The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the invention. The present invention further rel...  
WO/2018/055524A1
The present invention relates to pyrrolidine sulfonamide analogs (I), pharmaceutical compositions containing them and their use as TRPV4 antagonists.  
WO/2018/057588A1
Disclosed are chemical entities which are compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, R1, R2, E, n and Z are as defined herein. These chemical entities are useful as inhibitors of the PAR-2 sig...  
WO/2018/051877A1
The present invention addresses the problem of providing an organic pigment having stronger absorption in the long wavelength region. The problem can be solved by providing: a compound represented by formula (I) (In the formula, X1, X2, ...  
WO/2018/051239A1
The present invention provides improved, commercially viable and consistently reproducible processes for the preparation of pure and stable crystalline Raltegravir potassium Form 3 and pharmaceutical composition thereof.  
WO/2018/050584A1
The invention relates to spirobifluorene derivatives which are substituted with electrone transport groups, in particular for use in electronic devices. The invention further relates to a method for producing the compounds according to t...  
WO/2018/053302A1
The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of indoleamine-2,3-dioxygenase (IDO) activity, and methods of treating IDO-related disorders.  
WO/2018/050583A1
The present invention relates to carbazole derivatives which are substituted with electron transport groups, in particular for use in electronic devices. The invention further relates to a method for producing the compounds according to ...  
WO/2018/052945A1
The present disclosure provides compounds represented by Formula I and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, Ar, L, X, Y, and B are as defined as set forth in the speci...  
WO/2018/052725A1
Disclosed are novel stable violet-blue to blue imidazolium azo compounds that have a simplified chromophore and high relative solubility in aqueous systems, and that are stable under the conditions of use and storage. The compounds are u...  
WO/2018/051109A1
Provided herein are novel maytansinoid compounds of general formula I. Also provided herein are conjugates comprising the compounds linked to a binding protein via a linker, and conjugating reagents comprising the compounds attached via ...  
WO/2018/042362A1
The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present ...  
WO/2018/038938A1
Provided is a composition comprising a compound having structure (I) wherein each of A1, A2, A3, A4, A5, A6, A7, and A8 is independently CR12 or N; wherein one to four of A1, A2, A3, A4, A5, A6, A7, and A8 are N; wherein J1 is C or Si; w...  
WO/2018/038877A1
Fused [1,2]Imidazo[4,5-c] ring compounds (e.g., imidzao[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) substituted on the fused ring with a ...  
WO/2018/036469A1
Provided are a PDE4 inhibitor and a use thereof in the preparation of a medicament for treating PDE4 related diseases. Specifically disclosed are the compound as shown in formula (I) and a pharmaceutically acceptable salt thereof.  
WO/2018/032468A1
A novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I) and pharmaceutically acceptable salts thereof are described. The compositions comprising at least one Heterocycle-Substituted Tetracyclic Compound and methods of using ...  
WO/2018/033019A1
The present invention relates to an oxazolopyridine quaternary ammonium salt compound as shown in formula 1, a preparation method therefor and a conversion use thereof as a synthetic intermediate. The provided method for preparing the ox...  
WO/2018/032467A1
Disclosed are novel chromane-substituted tetracyclic compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, A', R2 R3, R4 and R5 are as defined in the description. Also disclosed are compositions comprising a...  
WO/2018/035005A1
The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A', R2 R3 and R5 are as defined herein. The present invention also relates...  
WO/2018/033086A1
Disclosed are a compound having xanthone as the core and applications thereof in an organic electroluminescent component. The compound has xanthone as the parent core and is connected to an aromatic heterocyclic group, thereby breaking m...  
WO/2018/035006A1
The present invention relates to novel Chromane-Substituted Tetracyclic Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, A', R2 R3, R4 and R5 are as defined herein. The present invention also relates to ...  
WO/2018/030550A1
The present invention relates to a compound that may have an ROR(gamma)t modulating activity and can thus be useful in the treatment of cancer.  
WO/2018/030466A1
The purpose of the present invention is to provide a heterocyclic compound that can have GCN2-inhibiting activity and is expected to be useful in the prevention and treatment of GCN 2-related diseases and the like, including cancer. Prov...  
WO/2018/026782A1
Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutica...  
WO/2018/024653A1
The present invention relates to compounds of general formula (I), wherein the groups R1, R2 and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and mod...  
WO/2018/022911A1
The present disclosure relates to certain macrocyclic kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same to treat disease.  
WO/2018/019300A1
The invention discloses an oral solid preparation containing any one, or a mixture of two or more of crystalline form I, II, III, and IV of the compound represented by formula (A). The oral solid preparation of the present invention disi...  
WO/2018/019254A1
The present invention discloses a diphenyl ketone-based compound and an application thereof in an organo-electroluminescent device. The compound has the properties of limited intermolecular crystallization, limited clustering, and excell...  
WO/2018/021447A1
The purpose of the present invention is to provide a novel compound having D3 receptor antagonistic effect. Provided are the following: a compound represented by formula (I) (in the formula, ring A is a heterocyclic ring, X1 groups are e...  
WO/2018/019297A1
Disclosed is an isoquinolinone compound as shown in formula (I) or a stereoisomer, pharmaceutically acceptable salt, solvate or crystal thereof, and a preparation thereof and a use thereof in the preparation of drugs for treating or prev...  
WO/2018/017639A1
Disclosed herein are methods for the treatment of Rett Syndrome and conditions relating to Rett Syndrome.  
WO/2018/015196A1
The present invention relates to novel (imidazo[1,2-a]pyridine-3-yl)methyl-substituted diazahetero-bicyclic compounds, to methods for preparing same, to their use alone or in combinations for the treatment and/or prevention of diseases, ...  
WO/2018/011160A1
The present invention relates to compounds of the formula (I) or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R4 are as described above. The compounds may be useful for the treatment or prophylaxis...  
WO/2018/011681A1
Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, a...  
WO/2018/011527A1
The present invention relates to reagents for reversibly protecting biological molecules. In particular, it relates to compounds derived from azaisotoic anhydride and the uses of same for protecting biological molecules, particularly enz...  
WO/2018/013948A1
Mitochondria-targeting potassium sensors and method(s) for making such sensors. The sensor shows a response to potassium and displays a 130-fold dynamic range of fluorescence intensity and high brightness. The sensors response to potassi...  
WO/2018/008920A1
Provided is a pharmaceutical composition for preventing and treating tumors, the pharmaceutical composition including an imidazooxazole derivative compound, a solvate, a stereoisomer, or a pharmaceutically acceptable salt thereof as an a...  
WO/2018/009417A1
Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to macrocyclic α-keto amide derivatives and their use as therapeutic agents.  
WO/2018/005328A1
This invention relates to deuterated forms of bictegravir, and pharmaceutically acceptable salts thereof. In one aspect, the invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein each of Y1, ...  
WO/2018/005881A1
Provided herein are compounds of formula (IA) and (III) useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in t...  
WO/2018/005192A1
Bifunctional compounds that increase uric acid excretion and reduce uric acid production, and monofunctional compounds that either increase uric acid excretion or reduce uric acid production. Methods of using these compounds for reducing...  
WO/2018/005591A1
The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or β-Arrestin agonists of ...  
WO/2018/002219A1
Fused aromatic bicyclic substituted 5-(2-amino-4-pyrimidinyl)- cyanoindoline derivatives (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-KB-inducing kinase (NIK - also known as MAP3K14) useful...  
WO/2018/005328A8
This invention relates to deuterated forms of bictegravir, and pharmaceutically acceptable salts thereof. In one aspect, the invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein each of Y1, ...  
WO/2017/221869A1
Provided is a method for producing a substituted polycyclic pyridone derivative. A method for producing a compound represented by formula (II), which is characterized in that a compound represented by formula (I) is reacted with a compou...  

Matches 1 - 50 out of 13,145